These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 3712391)

  • 1. The relationship between the acetylator and the sparteine hydroxylation polymorphisms.
    Harmer D; Evans DA; Eze LC; Jolly M; Whibley EJ
    J Med Genet; 1986 Apr; 23(2):155-6. PubMed ID: 3712391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetically determined sparteine oxidation and sulfadimidine acetylation polymorphism in patients with non-occupational urinary bladder cancer.
    Orzechowska-Juzwenko K; Niewiński P; Pawlik J; Milejski P; Dembowski J; Swiebodzki L; Lorenz J
    Mater Med Pol; 1994; 26(4):145-8. PubMed ID: 7666680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of concomitant isoniazid administration on determination of acetylator phenotype by sulphadimidine.
    Zysset T; Peretti E
    Eur J Clin Pharmacol; 1986; 30(4):463-6. PubMed ID: 3743623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Phenotypes of oxidation and acetylation in Alzheimer's disease--preliminary report].
    Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Leszek J; Rudzik J; Grotthus B
    Psychiatr Pol; 2007; 41(2):261-9. PubMed ID: 17598435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with hyperthyreosis].
    Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Forkasiewicz Z; Dawiskiba J; Bednarz W; Domosławski P
    Endokrynol Pol; 2006; 57(6):605-11. PubMed ID: 17253433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible optimization of sulphadimidine dosage for acetylator phenotyping.
    Hombhanje F
    Jpn J Pharmacol; 1991 Aug; 56(4):531-4. PubMed ID: 1744992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acetylator polymorphism in rheumatoid arthritis.
    Ladero JM; Andres MP; Bañares A; Fernández B; Hernández C; Benítez J
    Eur J Clin Pharmacol; 1993; 45(3):279-81. PubMed ID: 8276055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
    Clark DW
    Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers.
    Graf T; Broly F; Hoffmann F; Probst M; Meyer UA; Howald H
    Eur J Clin Pharmacol; 1992; 43(4):399-403. PubMed ID: 1451720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acetylation.
    Weber WW
    Birth Defects Orig Artic Ser; 1990; 26(1):43-65. PubMed ID: 2224079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic acetylator polymorphism in breast cancer patients.
    Ladero JM; Fernández MJ; Palmeiro R; Muñoz JJ; Jara C; Lázaro C; Pérez-Manga G
    Oncology; 1987; 44(6):341-4. PubMed ID: 3684174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical significance of the determination of oxidation and acetylation phenotype in patients with multiple sclerosis].
    Milejski P; Orzechowska-Juzwenko K; Pawlik J; Kamienowski J; Horoch E; Niewiński P; Hurkacz M
    Neurol Neurochir Pol; 1996; 30(4):571-9. PubMed ID: 9045059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapsone N-acetylation, metoprolol alpha-hydroxylation, and S-mephenytoin 4-hydroxylation polymorphisms in an Indonesian population: a cocktail and extended phenotyping assessment trial.
    Setiabudy R; Kusaka M; Chiba K; Darmansjah I; Ishizaki T
    Clin Pharmacol Ther; 1994 Aug; 56(2):142-53. PubMed ID: 8062490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between acetylator phenotype and intensity of the hypoglycaemic effect of a suplhonamide preparation in children with insulin-dependent diabetes.
    Hadasová E; Brysová V; Utĕsený J; Macků M
    Bratisl Lek Listy; 1991 Dec; 92(12):609-14. PubMed ID: 1806177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with Parkinson's disease].
    Milejski P; Orzechowska-Juzwenko K; Kamienowski J; Horoch E; Niewiński P; Hurkacz M; Rzemisławska Z
    Neurol Neurochir Pol; 1999; 33(5):1015-24. PubMed ID: 10672554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.
    Brøsen K; Davidsen F; Gram LF
    Br J Clin Pharmacol; 1990 Feb; 29(2):248-53. PubMed ID: 2306418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sparteine oxidation polymorphism in Denmark.
    Brøsen K; Otton SV; Gram LF
    Acta Pharmacol Toxicol (Copenh); 1985 Nov; 57(5):357-60. PubMed ID: 4090995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetylator phenotype in psoriasis.
    Jiménez-Nieto LC; Ladero JM; Fernández-Gundín MJ; Robledo A
    Dermatologica; 1989; 178(3):136-7. PubMed ID: 2721804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The genetic polymorphism of sparteine metabolism.
    Eichelbaum M; Reetz KP; Schmidt EK; Zekorn C
    Xenobiotica; 1986 May; 16(5):465-81. PubMed ID: 3739368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-acetylation and hydroxylation polymorphisms in type II diabetics with microvascular disturbances.
    Gawrońska-Szklarz B; Górnik W; Pawlik A; Kunicki P; Wójcicki J; Sitkiewicz D; Sych Z
    Eur J Clin Pharmacol; 1997; 51(6):431-5. PubMed ID: 9112055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.